Table 4 Efficacies of serum Egfl7, AFP or Parallel in differentiating early HCC from healthy individuals
Data | Testing Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|---|
Egfl7 | AFP | Parallel | Egfl7 | AFP | Parallel | |
Sensitivity | 77.4% | 65.3% | 88.9% | 75.9% | 58.9% | 86.7% |
Specificity | 82.2% | 97.2% | 79.9% | 79.1% | 97.1% | 76.2% |
Accuracy | 80.2% | 83.8% | 83.6% | 77.6% | 78.8% | 81.2% |
Omission diagnostic rate | 22.6% | 34.7% | 11.1% | 24.1% | 41.1% | 13.3% |
Mistake diagnostic rate | 17.8% | 2.8% | 20.1% | 20.9% | 2.9% | 23.8% |
Positive likelihood ratio | 4.34 | 23.5 | 4.42 | 3.63 | 20.3 | 3.64 |
Negative likelihood ratio | 0.28 | 0.36 | 0.14 | 0.30 | 0.42 | 0.17 |
Positive predict value | 0.76 | 0.95 | 0.76 | 0.77 | 0.95 | 0.77 |
Negative predict value | 0.83 | 0.79 | 0.91 | 0.78 | 0.72 | 0.86 |